Skip to content
OpenCapital
Get started

Kiniksa Pharmaceuticals International, plc KNSA Business Segments — Investment Income Interest

Similar metrics at other companies

Vertex Pharmaceuticals logo
VRTXPharmaceuticals — Interest income, net
$114.8M-2.6%
Ligand Pharmaceuticals logo
LGNDDevelopment and Licensing of Biopharmaceutical Assets — Interest Income
$6.66M+276%
Oruka Therapeutics, Inc. logo
ORKAInvestment Income Interest
$4.61M+12.6%
Vertex Pharmaceuticals logo
VRTXPharmaceuticals — income (loss)
$1.03B+59.6%
Ondas, Inc. logo
ONDSInvestment Income Interest
$12.14M+5,938%
Nelnet logo
NNIInvestment interest — Investment interest
$40.2M-2.9%

Other financials

Income statement

See full
Revenue$214.3M+55.5%
Gross profit$193.5M+61.3%
Operating income$29.3M+121%
Net income$22.6M+165%
EPS (diluted)$0.27+145%

Balance sheet

See full
Cash & equivalents$190.0M+20.9%
Total debt$9.0M-9.0%
Total equity$605.7M+32.4%
Total assets$825.3M+37.7%

Cash flow

See full
Operating cash flow$50.2M+125%
CapEx$161.0K+62.6%
Free cash flow$50.0M+125%

Valuation

See full
Market cap$4.24B+128%
Enterprise value$4.06B+139%
P/E58×—
P/S5.6×+1.8×

Profitability

See full
Gross margin89.3%+3.5pp
Operating margin12.4%+10.2pp
Net margin9.7%+7.6pp
FCF margin21.8%+12.2pp

Returns & leverage

See full
Return on equity13.7%+11.3pp
Debt / equity0×0.0×
Current ratio3.8×+0.1×

Where this comes from

Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kiniksa Pharmaceuticals International, plc's business segments — investment income interest.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kiniksa Pharmaceuticals International, plc's business segments — investment income interest?
Kiniksa Pharmaceuticals International, plc (KNSA) reported business segments — investment income interest of $3.41M in Q1 2026.
How has Kiniksa Pharmaceuticals International, plc's business segments — investment income interest changed year-over-year?
Kiniksa Pharmaceuticals International, plc's business segments — investment income interest increased by 49.1% year-over-year, from $2.29M to $3.41M.
What does business segments — investment income interest mean?
Represents the interest income generated from cash, cash equivalents, and marketable securities held by the pharmaceutical segment. This metric reflects the company's ability to earn returns on its idle capital reserves while awaiting deployment into clinical development or commercial activities.